Black Opal Ventures (BOV) is a Health Tech venture capital fund founded by two female GPs of color, Dr. Tara Bishop and Eileen Tanghal. Black Opal Ventures is committed to supporting diverse founders, increasing diversity on boards and management teams, and improving health outcomes for diverse populations. The Fund invests in Seed to Series B stage companies based in North America and Europe with a focus in digital healthcare, life sciences, wearables & diagnostics, and genomics. BOV recognizes that Health Tech carries a significant market opportunity in a large and growing sector that is primed for disruption by cutting edge technology. The fund’s investments are driven by its mission to create impactful health outcomes for diverse populations, including the reduction of health disparities, while creating financial returns.
Why We Invested
The opportunity to invest in a healthcare system that is equitable is more critical than ever. This investment is at the intersection of gender, technology, health and racial equity. The GP team is 100% female, and the fund is targeting 50% of portfolio company CEOs to be women or people of color. The fund’s investments optimize for the impact on health outcomes for diverse populations, including reduction of health disparities. The portfolio companies are also poised to benefit from strategic relationships with Eli Lilly as well as other LPs, including 3 healthcare systems, which we anticipate will strengthen the potential for the Fund to realize strong financial and impact returns.
Impact Sector: Health Tech
Deal Type: Venture capital